scholarly journals Novel therapies for pancreatic cancer: setbacks and progress

2010 ◽  
Vol 6 (7) ◽  
pp. 1061-1064 ◽  
Author(s):  
Han Hsi Wong ◽  
Nicholas R Lemoine
Keyword(s):  
Pancreatic Cancer ◽  
Novel Therapies

scholarly journals Novel therapies targeting hypoxia mechanism to treat pancreatic cancer

2021 ◽  
Vol 33 (2) ◽  
pp. 216-231
Author(s):  
Wenhao Luo ◽  
◽  
Jiangdong Qiu ◽  
Lianfang Zheng ◽  
Taiping Zhang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Novel Therapies

From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer

2019 ◽  
Vol 17 (2) ◽  
pp. 108-123 ◽  
Author(s):  
Christopher Nevala-Plagemann ◽  
Manuel Hidalgo ◽  
Ignacio Garrido-Laguna
Keyword(s):  
Pancreatic Cancer ◽  
State Of The Art ◽  
Advanced Stage ◽  
Novel Therapies

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

2015 ◽  
Vol 12 (6) ◽  
pp. 319-334 ◽  
Author(s):  
Ignacio Garrido-Laguna ◽  
Manuel Hidalgo
Keyword(s):  
Pancreatic Cancer ◽  
State Of The Art ◽  
Novel Therapies

Inhibition of pancreatic cancer cell growth and induction of apoptosis with novel therapies directed against protein kinase A

Surgery ◽  
2003 ◽  
Vol 134 (2) ◽  
pp. 197-205 ◽  
Author(s):  
Buckminster Farrow ◽  
Piotr Rychahou ◽  
Carlos Murillo ◽  
Kathleen L. O'Connor ◽  
Takeshi Iwamura ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Protein Kinase ◽  
Cell Growth ◽  
Protein Kinase A ◽  
Cancer Cell ◽  
Pancreatic Cancer Cell ◽  
Novel Therapies ◽  
Cancer Cell Growth ◽  
Induction Of Apoptosis ◽  
Kinase A

scholarly journals The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies

Biomedicines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 389
Author(s):  
Marwa Elsayed ◽  
Maen Abdelrahim
Keyword(s):  
Pancreatic Cancer ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Survival Rates ◽  
Vital Role ◽  
Screening Tests ◽  
Ductal Adenocarcinoma ◽  
Original Research ◽  
Novel Therapies ◽  
Early Screening ◽  
Search Tool

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in the US, and it is expected to be the second leading cause of cancer deaths by 2030. The lack of effective early screening tests and alarming symptoms with early undetectable micro-metastasis at the time of presentation play a vital role in the high death rate from pancreatic cancer. In addition to this, the low mutation burden in pancreatic cancer, low immunological profile, dense tumorigenesis stroma, and decreased tumor sensitivity to cytotoxic drugs contribute to the low survival rates in PDAC patients. Despite breakthroughs in chemotherapeutic and immunotherapeutic drugs, pancreatic cancer remains one of the solid tumors that exhibit meager curative rates. Therefore, researchers must dedicate more effort to understanding the pathology and immunological behavior of PDAC, in addition to properly utilizing more advanced screening modalities and new therapeutic agents. In our review, we focus mainly on the latest updates from clinical guidelines and novel therapies that have been recently investigated or are under investigation for PDAC. We used PubMed as a search tool for finding original research articles addressing the latest developments in diagnosing and treating PDAC. Additionally, we also used the clinical trials published on clinicaltrialsgov as sources for our data.

Clinical trials in pancreatic cancer: A comprehensive analysis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16730-e16730
Author(s):  
Erryk Stephan Katayama ◽  
Jonathan J. Hue ◽  
David Lawrence Bajor ◽  
Lee Mayer Ocuin ◽  
John Brian Ammori ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Trials ◽  
Early Stage ◽  
Clinical Stage ◽  
Comprehensive Analysis ◽  
Phase Iii ◽  
Novel Therapies ◽  
New Paradigm ◽  
Therapeutic Trials ◽  
Novel Therapeutic Strategies

e16730 Background: Pancreatic cancer is the most aggressive of common cancers and desperately in need of novel therapies. Unlike many other common cancers, there have been no new paradigm-changing therapies in the past 40 years beyond chemotherapy. The most urgent question in the field then is what is coming down the pike? In this study, we perform the first comprehensive analysis of the current clinical trial landscape in pancreatic cancer to better understand the pipeline of new therapies. Methods: We queried clinicaltrials.gov for registered pancreatic cancer clinical trials. Studies were curated and categorized according to the phase of study, the clinical stage of the study population, the type of the intervention under investigation, and the biologic mechanism targeted by the therapy. This compendium revealed the full landscape of investigational therapeutic trials. Results: As of May 18, 2019, there were 440 total trials testing 600 distinct interventions. 104 of these trials spanned multiple phases, yielding 544 trials across phases. These included 38 trials (8.6%) in phase III testing, 269 (61%) in phase II, and 237 (54%) in phase I. With respect to therapeutic category, 186 (31%) were investigating immunotherapies, 66 (11%) targeted cell signaling pathways, 140 (23%) targeted cell cycle or DNA biology, and 32 (5%) targeted metabolic pathways. Of the 38 phase III trials, only 10 are currently testing novel drugs that are not already FDA approved or routinely used in patients for another indication. Conclusions: A large number of novel therapeutic strategies are currently under investigation. They include a broad range of therapies targeting diverse biologic processes. However, only a small number of novel therapies are in late-stage testing, suggesting that future progress is likely several years away, and dependent on the success of early-stage trials. [Table: see text]

scholarly journals Immunotherapy in pancreatic cancer treatment: a new frontier

2016 ◽  
Vol 10 (1) ◽  
pp. 168-194 ◽  
Author(s):  
Komal Thind ◽  
Leslie J. Padrnos ◽  
Ramesh K. Ramanathan ◽  
Mitesh J. Borad
Keyword(s):  
Pancreatic Cancer ◽  
Tumor Microenvironment ◽  
Pancreatic Tumor ◽  
Standard Of Care ◽  
Current Treatment ◽  
Novel Therapies ◽  
Potential Treatment ◽  
The Past ◽  
New Frontier ◽  
Resistance To Chemotherapy

Pancreatic cancer is a highly aggressive and lethal cancer characterized by high invasiveness, local and extensive dissemination at time of diagnosis and resistance to treatment. Few therapies have shown efficacy in the past and even standard of care therapies yield only modest improvements in the mortality of patients with advanced or metastatic disease. Efforts have been undertaken to study the pancreatic tumor microenvironment and have established its complex and immunosuppressive nature which could explain the high resistance to chemotherapy. Novel therapies targeting the tumor microenvironment with an aim to decrease this resistance, improve immune tolerance and increase the efficacy of the current treatment have shown some promising preliminary results in preclinical and clinical trials. We review the current advances in the field of immunotherapy and their effectiveness as a potential treatment strategy in the pancreatic cancer.

scholarly journals Recent Advances in Nanoparticle-Mediated Diagnosis and the Treatment of Pancreatic Cancer

2021 ◽  
Vol 22 (15) ◽  
pp. 8060
Author(s):  
Andreea Nedelcu ◽  
Teodora Mocan ◽  
Cristiana Grapa ◽  
Lucian Mocan
Keyword(s):  
Pancreatic Cancer ◽  
Surgical Treatment ◽  
Survival Rate ◽  
Solid Tumors ◽  
Present Review ◽  
Novel Therapies ◽  
Curative Intent ◽  
Recent Advances ◽  
Exciting Opportunity

Pancreatic cancer (PC), one of the most lethal solid tumors in humans, has a five-year survival rate of only 4%. Surgical treatment is the only accepted therapy with curative intent because the vast majority of these tumors are chemoresistant. Unfortunately, due to the aggressive nature of these tumors, fewer than 20% are resectable when the first symptoms occur. Novel therapies are required to overcome all these therapeutic issues, and the development of active nanocarriers represents an exciting opportunity to improve PC outcomes. The present review focuses on recent advances in the field of nanotechnology with application in PC treatment.

scholarly journals Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 987
Author(s):  
Andreas Domen ◽  
Delphine Quatannens ◽  
Sara Zanivan ◽  
Christophe Deben ◽  
Jonas Van Audenaerde ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Extracellular Matrix ◽  
Growth Factors ◽  
Cancer Metastasis ◽  
Therapy Resistance ◽  
Cancer Therapies ◽  
Cancer Associated Fibroblasts ◽  
Novel Therapies ◽  
The Past ◽  
Drug Access

Cancer arises from mutations accruing within cancer cells, but the tumor microenvironment (TME) is believed to be a major, often neglected, factor involved in therapy resistance and disease progression. Cancer-associated fibroblasts (CAFs) are prominent and key components of the TME in most types of solid tumors. Extensive research over the past decade revealed their ability to modulate cancer metastasis, angiogenesis, tumor mechanics, immunosuppression, and drug access through synthesis and remodeling of the extracellular matrix and production of growth factors. Thus, they are considered to impede the response to current clinical cancer therapies. Therefore, targeting CAFs to counteract these protumorigenic effects, and overcome the resistance to current therapeutic options, is an appealing and emerging strategy. In this review, we discuss how CAFs affect prognosis and response to clinical therapy and provide an overview of novel therapies involving CAF-targeting agents in lung and pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document